Alemtuzumab

Generic Name
Alemtuzumab
Brand Names
Campath, Lemtrada, MabCampath
Drug Type
Biotech
Chemical Formula
-
CAS Number
216503-57-0
Unique Ingredient Identifier
3A189DH42V
Background

Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regio...

Indication

用于烷化剂氟达拉滨(fludarabine)治疗失败的B细胞性慢性淋巴细胞白血病患者;亦可用于复发缓解型多发性硬化症治疗。

Associated Conditions
B-Cell Chronic Lymphocytic Leukemia, Kidney Transplant Rejection, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Steroid Refractory Acute Graft Versus Host Disease, T-cell Prolymphocytic Leukemia (T-PLL), Refractory Autoimmune Hemolytic Anemia, Refractory Idiopathic thrombocytopenic purpura
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy

Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients

First Posted Date
2005-03-11
Last Posted Date
2012-12-27
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
27
Registration Number
NCT00105235
Locations
🇺🇸

University of Miami School of Medicine, Miami, Florida, United States

🇺🇸

University of California, San Francisco, San Francisco, California, United States

🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

and more 6 locations

Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL

First Posted Date
2003-12-11
Last Posted Date
2023-06-29
Lead Sponsor
Eastern Cooperative Oncology Group
Target Recruit Count
102
Registration Number
NCT00074282
Locations
🇺🇸

Cancer Center of Kansas-Independence, Independence, Kansas, United States

🇺🇸

Marshfield Clinic at Saint Michael's Hospital, Stevens Point, Wisconsin, United States

🇺🇸

Case Comprehensive Cancer Center, Cleveland, Ohio, United States

and more 140 locations

Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias

First Posted Date
2003-05-29
Last Posted Date
2024-02-29
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
130
Registration Number
NCT00061568
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome

First Posted Date
2003-01-27
Last Posted Date
2023-11-14
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
5
Registration Number
NCT00047060
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma

Phase 1
Terminated
Conditions
First Posted Date
2003-01-17
Last Posted Date
2015-03-05
Lead Sponsor
Genzyme, a Sanofi Company
Target Recruit Count
61
Registration Number
NCT00051701

Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia

Phase 3
Completed
Conditions
First Posted Date
2002-10-02
Last Posted Date
2016-07-28
Lead Sponsor
Genzyme, a Sanofi Company
Target Recruit Count
284
Registration Number
NCT00046683
© Copyright 2024. All Rights Reserved by MedPath